Oral Cyclophosphamide and Etoposide in Treatment of Malignant Pleural Mesothelioma
Seyda Gunduz et al
Abstract
Background: Malignant mesothelioma (MM) is almost always fatal and few treatment options are available.
The aim of this study was to evaluate the efficacy of oral cyclophosphamide and etoposide for patients who
underwent standard treatment for advanced MM. Materials and Methods: This study included 22 malignant
pleural mesothelioma patients who were treated with oral cyclophosphamide and etoposide (EE). Results: The
average follow-up period of the patients was 39.1 months. Under the treatment of oral EE, median progressionfree
survival was 7.7 months [95%CI HR (4.3-11.1)] and median overall survival was 28.1 months [95%CI HR
(5.8-50.3)]. The treatment response rates were as follows: 4 patients (27.3%) had a partial response (PR), 12
(54.5%) had stable disease (SD), and progressive disease (PD) was observed in 6 (35.9%). Conclusions: Oral
EE can be administered effectively to patients with inoperable malignant mesothelioma who had previously
received standard treatments.
APJCP Editorial Office : National Cancer Center, Korea. Tel : +82-31-920-1938 Fax : +82-31-920-1939
E-mail : apjcpedit@gmail.com
323 Ilsan-ro, Ilsandong-gu, Goyang-si Gyeonggi-do, 410-769, Republic of Korea
Copyright ⓒ National Cancer Center, Korea. All Rights Reserved.
